Research programme: mucin 5B protein inhibitors - Parion Sciences
Alternative Names: Mucolytic agents - Parion Sciences; Pulmonary mucolytics - Parion SciencesLatest Information Update: 21 Jul 2023
At a glance
- Originator Parion Sciences
- Class Mucolytics
- Mechanism of Action Antioxidants; Mucin 5B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Lung disorders
Highest Development Phases
- Preclinical Lung disorders
Most Recent Events
- 13 Jul 2023 Mucin 5B protein inhibitors - Parion Sciences is available for licensing as of 13 Jul 2023. https://www.parion.com/partnership/ (Parion Sciences website, July 2023)
- 13 Jul 2023 Preclinical trials in Lung disorders in USA (unspecified route) prior to July 2023 (Parion Sciences pipeline, July 2023)